Hope for rare bone disease: first drug trial launches
NCT ID NCT07541209
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times
Summary
This study tests a new drug called PTH-IA for Jansen's Metaphyseal Chondrodysplasia (JMC), a very rare genetic disorder that causes severe bone problems, short stature, and kidney issues. About 12 adults and children will receive the drug to see if it is safe and works. The goal is to control the disease and improve quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JANSEN'S METAPHYSEAL CHONDRODYSPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States